Studies investigating the effects of achieving clinic systolic BP (SBP) targets of <140 mm Hg have shown that some patient populations may benefit more with intensive targets than others. The ACCORD trial (Action to Control Cardiovascular Risk in Diabetes), conducted in high-risk hypertensive patients with type 2 diabetes mellitus, showed that intensive therapy to achieve a clinic SBP of <120 mm Hg did not significantly reduce the rate of nonfatal myocardial infarction (MI), nonfatal stroke, or CVD death compared with standard therapy. 6 Similarly, the SPS3 trial (Secondary Prevention of Small Subcortical Strokes) showed that intensive therapy (target clinic SBP <130 mm Hg) resulted in nonsignificant reductions in the rate of stroke compared with standard therapy (clinic SBP of 130-<140 mm Hg) in patients with recent lacunar stroke. 7 Among patients at high CVD risk (excluding those with diabetes mellitus or a prior stroke), SPRINT (Systolic Blood Pressure Intervention Trial) showed that intensive therapy (clinic SBP, <120 mm Hg) significantly reduced the rate of MI, other acute coronary syndromes, stroke, heart failure, or CVD death compared with standard therapy (clinic SBP, <140 mm Hg), 8 indicating that a lower SBP goal may be more beneficial than the standard target goal for CVD prevention in these patients. However, in intermediate-risk patients without CVD, the HOPE-3 (Heart Outcomes Prevention Evaluation-3) showed that treatment with candesartan plus hydrochlorothiazide did not significantly lower the incidence of nonfatal MI, nonfatal stroke, or CVD death compared with placebo. 9 Because the benefit of antihypertensive therapy for mildly hypertensive patients without comorbidities is uncertain, the National Heart Foundation of Australia guidelines recommend target BP levels <140/90 mm Hg in patients with uncomplicated mild hypertension, 10 whereas they recommend a target SBP <120 mm Hg in high-risk patients.
The HONEST study (Home Blood Pressure Measurement With Olmesartan Naive Patients to Establish Standard Target Blood Pressure) investigated the association of home and clinic BPs with the incidence of CVD. 11, 12 HONEST was a large-scale, prospective, observational study involving 21 591 Japanese patients with hypertension receiving an olmesartan-based antihypertensive treatment. HONEST revealed that the incidence of stroke, MI, coronary revascularization procedures for angina pectoris, or sudden death significantly increased in patients with a morning home SBP of 145 to <155 mm Hg and ≥155 mm Hg compared with patients with a morning home SBP of <125 mm Hg. CVD risk was also significantly higher in patients with a morning home SBP of ≥145 mm Hg and a clinic SBP of <130 mm Hg compared with patients with a morning home SBP of <125 mm Hg and clinic SBP of <130 mm Hg. These results suggest that control of morning home BP may be essential.
The aim of this post hoc analysis of the HONEST trial was to explore the association between BP control based on home BP and the incidence of CVD among Japanese patients with various levels of cardiovascular risk.
Methods

Study Design
The anonymized data that support the findings of this study are available from the corresponding author on reasonable request. This was a post hoc analysis of the HONEST study, whose protocol and primary results have already been reported. 11, 12 Briefly, HONEST was a large-scale, prospective, 2-year observational study (clinical study registration: UMIN000002567), which enrolled Japanese outpatients with essential hypertension who were starting treatment with olmesartan at the participating physician's discretion. Patients were excluded if they had a history of recent CVD events or if cardiovascular intervention was planned. The study protocol was approved by the Ethics Committee of Daiichi Sankyo, Co, Ltd, conformed with the pharmaceutical affairs laws of Japan and was approved by the Ministry of Health, Labor, and Welfare of Japan before commencement. This study was performed at medical institutions registered in compliance with Good Postmarketing Study Practice in Japan and internal regulations for clinical studies at each institution. Written informed consent was obtained from all patients before registration of the study.
In this analysis, patients in the HONEST study were stratified according to risk level and classified as follows: SPRINT population, SPRINTexcluded high-risk population, and non-SPRINT low-risk population.
The SPRINT population consisted of patients who would have been eligible for SPRINT, 8 were ≥50 years old, did not have diabetes mellitus or prior stroke, and had an increased CVD risk. Patients also had to fit one of the following SBP criteria: 130 to 180 mm Hg on no or 1 medication; 130 to 170 mm Hg on 2 medications; 130 to 160 mm Hg on 3 medications; or 130 to 150 mm Hg on 4 medications. In SPRINT, an increased CVD risk was defined as one of the following: presence of clinical CVD (previous MI, coronary revascularization procedure, peripheral artery disease, angina pectoris, and left ventricular hypertrophy), CKD (estimated glomerular filtration rate, 20-59 mL/min per 1.73 m 2 ), Framingham CVD risk score ≥15%, or ≥75 years old. The SPRINT-excluded high-risk population consisted of all patients in HONEST who had diabetes mellitus or prior stroke. The non-SPRINT low-risk population consisted of patients enrolled in HONEST who did not meet the inclusion criteria of the SPRINT and the SPRINT-excluded high-risk populations.
Outcomes
Outcomes of the HONEST study have been described previously. 11, 12 CVD events were defined as composite events of stroke (atherothrombotic cerebral infarction, lacunar infarction, cerebral hemorrhage, unclassified cerebral infarction, subarachnoid hemorrhage, cardiogenic cerebral infarction, or unclassified stroke), coronary artery disease (CAD; coronary revascularization procedure for angina pectoris or MI), or sudden death. Renal events were defined as composite events of end-stage renal disease or doubling of serum creatinine. In this analysis, SPRINT events were also included as an outcome, which was defined as composite events of stroke, CAD, hospitalization for heart failure, or sudden death.
BP Measurements
A full description of how BP was measured in the HONEST study has been published previously. 11, 12 Briefly, home BP was measured at 1, 4, and 16 weeks and 6, 12, 18, and 24 months using an electric device twice in the morning and twice at bedtime, with the average of each calculated. In analyses of the relationship with the incidence of cardiovascular events, the average BP during the follow-up period was used. For patients who had cardiovascular events, the average of obtained BP values until the first occurrence of such events was used.
Statistical Analysis
The analysis population comprised eligible patients who received olmesartan at least once during the treatment period. Incidence of events is presented as events per 1000 person-years. Hazard ratios (HRs) for CVD events were estimated using the Cox proportional hazards regression model after adjustment for sex, age, family history of CVD, dyslipidemia, diabetes mellitus, CKD, history of CVD, and smoking status. The maximum contrast statistic was used to evaluate the relationship between SBP and CVD event risk in each patient group. 13 The following 5 contrast vectors were used in this analysis: J-curve association (−1, −4, −4, 1, 6), linear association (−2, −1, 0, 1, 2), curvilinear association 1 (−4, −3, −1, 2, 6), curvilinear association 2 (−6, −6, −1, 4, 9), and curvilinear association 3 (−1, −1, −1, −1, 4). All statistical tests were 2 sided, using a significance level of 0.05. SAS release 9.2 software (SAS Institute, Cary, NC) was used for all statistical analyses.
Results
Patient Characteristics
Of the 21 591 Japanese patients included in HONEST, 5823 met the SPRINT population criteria (27.0%), 5481 met the SPRINT-excluded high-risk population criteria (25.4%), and 10 287 met the non-SPRINT low-risk population criteria (47.6%; Figure 1 ). The SPRINT population and the SPRINTexcluded high-risk population showed higher rates of preexisting disease and comorbidity than the non-SPRINT low-risk population (Table 1 ). In the SPRINT-excluded high-risk population, 26.1% had prior stroke, and 80.8% had diabetes mellitus. The frequencies of preexisting CAD and complications of cardiac disease were similar between the SPRINT population (7.3% and 14.0%, respectively) and the SPRINT-excluded high-risk population (7.7% and 13.0%, respectively). In the SPRINT-excluded high-risk population, 28.0% of patients had CKD complications (CKD alone or with other comorbidities), whereas in the SPRINT population, a larger proportion of patients had CKD complications (34.6%). Notably, at baseline, in the SPRINT-excluded high-risk population, 3108 patients (56.7%) had diabetes mellitus alone, 298 patients (5.4%) had CKD alone, 758 patients (13.8%) had stroke alone, and 1245 patients (22.7%) had diabetes mellitus and CKD.
Incidence of Outcomes by CVD Risk
The incidence of CVD events was the highest in the SPRINTexcluded high-risk population (12.41 per 1000 person-years), followed by the SPRINT population (6.32 per 1000 personyears) and the non-SPRINT low-risk population (3.39 per 1000 person-years; Table 2 ). Rates of SPRINT events, stroke, CAD, all-cause death, and CVD death were also the highest in the SPRINT-excluded high-risk population. The incidence of renal events was the highest in the SPRINT-excluded high-risk population (3.97 per 1000 person-years), followed by the SPRINT population and the non-SPRINT low-risk population, which had similar incidences (0.85 and 0.63 per 1000 person-years, respectively). In the SPRINT-excluded high-risk population, patients with diabetes mellitus showed a higher rate of CAD events (6.26 per 1000 person-years) than the other populations, and patients with prior stroke showed a higher rate of stroke events (11.0 per 1000 person-years) than the other populations ( Table 2) .
Relationship Between CVD and Morning Home SBP
In the non-SPRINT low-risk population, lower SBP was associated with numerically lower CVD incidence among patient groups with a morning home SBP of ≥155, 145 to <155, and 135 to <145 mm Hg. On the contrary, the incidence rate of CVD events was numerically higher among patients with a morning home SBP of 125 to 135 and <125 mm Hg compared with patients with a morning home SBP of 135 to <145 mm Hg (Figure 2A ). However, in the non-SPRINT low-risk population, the incidence rate of CVD events was significantly increased only in patients with a morning home SBP of ≥155 mm Hg compared with those with a home SBP of <125 mm Hg (P<0.01; Figure 2A ). In contrast, in the SPRINT population and the SPRINT-excluded high-risk population, the lower home SBP group showed a lower CVD incidence with the lowest event rates at a home SBP of <125 mm Hg ( Figure 2B and 2C). Compared with the reference category (morning home SBP of <125 mm Hg), the HRs in each morning home SBP category presented a similar increasing trend as the BP increased in the SPRINT and the SPRINT-excluded high-risk populations, whereas HRs in the non-SPRINT low-risk population followed a J curve with the lowest HR in the home SBP category of 135 to <145 mm Hg ( Figure 2D through 2F). HR in a home SBP category of ≥155 mm Hg significantly increased compared with the reference home SBP category of <125 mm Hg in the non-SPRINT low-risk population (HR, 4.17; 95% CI, 1.88-9.24) and the SPRINT population (HR, 6.55; 95% CI, 2.03-21.18; Figure 2D and 2E). In the non-SPRINT low-risk population, the HR in the home SBP category of 135 to <145 mm Hg significantly decreased (HR, 0.43; 95% CI, 0.20-0.95; Figure 2D ). In the SPRINT-excluded high-risk population, HRs significantly increased in the home SBP categories of 145 to <155 mm Hg (HR, 2.60; 95% CI, 1.16-5.81) and ≥155 mm Hg (HR, 6.04; 95% CI, 2.62-13.93; Figure 2F ).
Relationship Between CVD and Clinic SBP
In the non-SPRINT low-risk population, SPRINT population, and SPRINT-excluded high-risk population, lower clinic SBP groups showed a lower CVD incidence among patient groups with a clinic SBP of ≥160, 150 to <160, 140 to <150, and 130 to 140 mm Hg, while a reduction in the incidence was unclear in patient groups with a clinic SBP of <130 mm Hg ( Figure 3A through 3C). It is noteworthy that an association between a lower clinic SBP and reduction in CVD risk at lower BP levels is uncertain, especially in a high-risk population. The event risk in the SPRINT-excluded high-risk population was similar in patient groups with a clinic SBP of <130 and 150 to <160 mm Hg (Figure 3D through 3F) .
Relationship Between CVD Risk and BP With Maximum Contrast Method
Maximum contrast method was used to investigate the relationship between BP and CVD risk by assigning 3 types of associations: J-curve association, linear association, and curvilinear association ( Figure S1 in the online-only Data Supplement). The non-SPRINT low-risk population showed a distinct relationship between BP and event risk compared with the SPRINT population and the SPRINT-excluded high-risk population (Table 3) . As a best fit, the relationship between the morning home SBP and event risk followed a nonsignificant J-curve association in the non-SPRINT low-risk population and a curvilinear association in the SPRINT population and the SPRINT-excluded high-risk population. In contrast, the relationship between clinic SBP and event risk in all of the populations followed a curvilinear association that showed a remarkable increase in risk at high BP levels. Numbers presented are n (%) or mean±SD. ACE, angiotensin-converting enzyme; BP, blood pressure; CAD, coronary artery disease; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NGSP, National Glycohemoglobin Standardization Program; SBP, systolic blood pressure; and SPRINT, Systolic Blood Pressure Intervention Trial.
Discussion
In this post hoc analysis of the HONEST study, we demonstrated that in high-risk hypertensive Japanese patients (the SPRINT and the SPRINT-excluded high-risk populations), a lower home SBP was associated with lower CVD risk, with the lowest risk in patients with a home SBP <125 mm Hg, whereas among low-risk Japanese patients (non-SPRINT low-risk population), CVD risk showed a J-curve association with on-treatment home SBP, with the lowest risk at a home SBP of 135 to <145 mm Hg. These results support the strict home BP target of <130/80 mm Hg recommended in the 2017 American College of Cardiology/American Heart Association guidelines, particularly for high-risk patients with hypertension. 5 On the contrary, similarly strict BP targets may not be necessary for low-risk patients with hypertension.
In this analysis of the HONEST study, the rates of CVD events risk in the SPRINT-excluded high-risk population was double compared with the SPRINT population. The event risk of the SPRINT population was twice that of the non-SPRINT low-risk population.
SPRINT High-Risk Population
The present post hoc analysis of the HONEST study revealed that in the SPRINT population, lower morning home SBP was associated with a reduction in CVD risk, with the lowest risk observed in patients with a home SBP of <125 mm Hg, although the association of lower clinic SBP with lower event risk was not observed in the patient group with a clinic SBP of <130 mm Hg. The method of BP measurement used in SPRINT was based on a mean of 3 BP measurements with an automated device while the patient was seated in a room without clinicians and after 5 minutes of quiet rest (automated office BP). The automated office BP is considered to be similar to a home BP measurement because it is performed under conditions in which white-coat hypertension has been mostly eliminated. 10 Therefore, this post hoc analysis of the SPRINT population in the HONEST study indicates that lowering the home SBP to a target goal of <125 mm Hg may be beneficial, and this finding is consistent with the results of SPRINT, which showed benefit of controlling SBP to target levels of <120 mm Hg.
SPRINT-Excluded High-Risk Population
In this study, the SPRINT-excluded high-risk population (with diabetes mellitus or previous history of stroke) had a higher risk than the SPRINT population and showed the effect of lowering the morning home SBP on reduction of CVD event risk in all patient categories, with the lowest risk observed with a morning home SBP of <125 mm Hg. The ACCORD study demonstrated that, among hypertensive patients with type 2 diabetes mellitus, the intensive-therapy group (SBP, <120 mm Hg) did not show significantly reduced rates of the primary outcome of nonfatal MI, nonfatal stroke, or CVD death (1.87% per year; HR, 0.88; 95% CI, 0.73-1.06; P=0.20) compared with the standard-therapy group (SBP, <140 mm Hg; 2.09% per year). 6 In the ACCORD study, the CAD event rate was much higher than that of stroke events (intensive-therapy group, 2.31% versus 0.32% per year; standard-therapy group, 2.41% versus 0.53% per year). In the group of patients with diabetes mellitus in the SPRINT-excluded high-risk population in the HONEST study, the rates of CAD and stroke events were 6.26 and 4.02 events per 1000 patient-years, respectively, which indicates that the ratio of CAD events to the total CVD events in the present study was much lower than that in the ACCORD study. Given the low CAD rate because of the relatively high stroke rate in Japan, these results of the HONEST study are compatible with the results of the ACCORD study.
The HOMED-BP study (Hypertension Objective Treatment Based on Measurement by Electric Devices of Blood Pressure) investigated the association between on-treatment home BP and CVD incidence. 14 In the post hoc analysis of the HOMED-BP study comparing 2 groups of patients with impaired glucose metabolism and normal glucose metabolism, the CVD event rates for impaired glucose metabolism patient groups with home SBP of <115, 115 to <125, and ≥125 mm Hg were 2.23, 7.85, and 12.64 per 1000 patient-years, respectively, indicating that a lower home SBP was associated with reduction in the CVD event rate (CVD death, nonfatal stroke, and nonfatal MI). 15 The results of the HOMED-BP study were similar to the results of the SPRINT-excluded high-risk population, 80% of which consisted of patients with diabetes mellitus, in the present study.
The SPS3 study reported a nonsignificant reduction of the rate of the primary outcome of all stroke with intensive therapy (2.25% per year) compared with standard therapy (2.77% per year; HR, 0.81; 95% CI, 0.64-1.03; P=0.08). 7 In addition, a post hoc analysis of the SPS3 study revealed a J-curve association between SBP and the incidence of stroke events, with the lowest risk of stroke events observed at an SBP of 124 mm Hg.
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High-Risk Versus Low-Risk Population
The present post hoc analysis of the HONEST study showed that in the high-risk hypertensive patients (the SPRINT and the SPRINT-excluded high-risk populations), the clinic SBP tended to show a nonsignificant J-curve association with CVD events, but home SBP did show the lowest risk in the patient group with a home SBP of <125 mm Hg. Therefore, this study suggests that strict BP control based on morning home SBP has the most benefit for the highest risk population of Japanese patients with diabetes mellitus and prior stroke. On the contrary, the non-SPRINT low-risk population showed a J-curve association between morning home SBP and CVD event risk with the lowest risk for home SBP of 135 to <145 mm Hg. Therefore, the results of this study indicate that intensive therapy may not be necessary for Japanese low-risk patients with hypertension (nonelderly with no risk factors for CVD) and that lowering of the BP to a clinic SBP of <140 mm Hg or a home SBP of <135 mm Hg might be sufficient, as the current guidelines recommend. Furthermore, in the HOPE-3 study, antihypertensive therapy for patients with lower BP who did not have CVD did not reduce the incidence of CVD. 9 An Australian guideline has also reported that the effects of lowering the BP on a reduction in CVD event rates among uncomplicated patients with lower BP have been uncertain. 
Study Limitations
Because the HONEST study is an observational study, the observed J-shaped relationship may be because of reverse causality. In addition, the number of events is relatively small during relatively shorter 2-year follow-up period, the J-curve of morning home BP and CV events found in the lower risk group might not be definitive. The novelty of this study is the comparison of the higher versus lower risk hypertensives, and we clarified that those with higher CV risk need faster strict morning home BP control, whereas those with lower risk may have longer time to control BP. Despite these limitations, we expect that the present observational study, which investigates the relationship between on-treatment home BP and CVD event incidence by stratifying hypertensive patients in routine clinical practice according Figure S1 .
to risk level, will motivate physicians to confirm the efficacy of home BP management based on cardiovascular risk levels.
Perspectives
In conclusion, it is essential to control the morning home SBP with different target goals according to the cardiovascular risk levels of the hypertensive Japanese patients. For high-risk patients, intensive therapy with a morning home SBP target of <125 mm Hg would be beneficial to reduce the CVD event risk. Because of lower CVD incidence in the lower BP categories and the possibility of reverse causality in this observational study, a large and longer intervention study based on home BP that demonstrated this point is needed in the comparing of the higher risk versus lower risk groups.
